A detailed history of Private Capital Group, LLC transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Private Capital Group, LLC holds 426 shares of HCM stock, worth $6,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
426
Previous 1,121 62.0%
Holding current value
$6,091
Previous $21,000 76.19%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 28, 2022

SELL
$8.59 - $20.77 $5,970 - $14,435
-695 Reduced 62.0%
426 $5,000
Q1 2022

Apr 21, 2022

BUY
$15.52 - $35.65 $1,086 - $2,495
70 Added 6.66%
1,121 $21,000
Q4 2021

Jan 24, 2022

BUY
$28.89 - $35.33 $982 - $1,201
34 Added 3.34%
1,051 $37,000
Q3 2021

Oct 13, 2021

BUY
$35.66 - $42.94 $5,812 - $6,999
163 Added 19.09%
1,017 $37,000
Q2 2021

Jul 26, 2021

BUY
$23.7 - $39.27 $2,749 - $4,555
116 Added 15.72%
854 $34,000
Q1 2021

Apr 12, 2021

SELL
$27.01 - $36.8 $270 - $368
-10 Reduced 1.34%
738 $21,000
Q4 2020

Jan 26, 2021

SELL
$27.51 - $34.36 $137 - $171
-5 Reduced 0.66%
748 $24,000
Q3 2020

Nov 12, 2020

BUY
$25.8 - $34.61 $1,341 - $1,799
52 Added 7.42%
753 $24,000
Q1 2020

May 07, 2020

BUY
$15.19 - $29.51 $2,475 - $4,810
163 Added 30.3%
701 $13,000
Q4 2019

Feb 14, 2020

SELL
$17.17 - $25.95 $2,747 - $4,152
-160 Reduced 22.92%
538 $13,000
Q3 2019

Nov 13, 2019

BUY
$17.84 - $22.69 $12,452 - $15,837
698 New
698 $13,000
Q2 2019

Aug 15, 2019

SELL
$22.0 - $31.78 $15,752 - $22,754
-716 Closed
0 $0
Q1 2019

Apr 26, 2019

BUY
$21.27 - $30.58 $744 - $1,070
35 Added 5.14%
716 $22,000
Q4 2018

Jan 28, 2019

BUY
$23.09 - $37.69 $15,724 - $25,666
681 New
681 $16,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.